



ASX ANNOUNCEMENT

29 December 2023

PROSPECTUS DESPACHED

CardieX Limited (ASX: CDX) (**CardieX**, the **Company**) is pleased to announce that the Company has completed the despatch of the prospectus dated 19 December 2023 (**Prospectus**) for its non-renounceable pro-rata entitlement offer of 1 new fully paid ordinary share (**Share**) for every 2.87 existing Shares held by eligible shareholders at an issue price of \$0.08 per new Share, together with 1 quoted option for every 3 new Shares subscribed for and issued, to raise up to approximately \$4.0 million (**Entitlement Offer**).

Eligible shareholders may access a copy of the Prospectus, along with their personalised application form, by accessing: <https://investor.automic.com.au/#/home>

Eligible shareholders are all shareholders with a registered address in Australia or New Zealand as at the record date, or are a shareholder that the Company has otherwise determined is eligible to participate in the Entitlement Offer.

Eligible shareholder should read the Prospectus carefully before making any investment decision regarding the Entitlement Offer. If you are in doubt about the Entitlement Offer, you should consult your professional adviser.

The closing date of the Entitlement Offer is 5:00pm (AEDT) on Thursday, 1 February 2024 (unless extended).

Notifications have also been sent to ineligible shareholders pursuant to ASX Listing Rule 7.7.1(b).

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton
melissa.hamilton@mcpartners.com.au

Investor Relations – USA

Matt Selinger
Managing Director, Integrous Communications
mselinger@integcom.com

About CardieX

CardieX is a medical technology company that develops and markets non-invasive patient monitoring technologies for assessing vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. CardieX is listed on the Australian Stock Exchange ("CDX").